2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 426

The Risk of Hospitalized Infection Following Initiation of Biologic Agents Versus Methotrexate in the Treatment of Juvenile Idiopathic Arthritis
Abstract Number: 427

The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis
Abstract Number: 428

Use of Rituximab Compared to Anti-TNF Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: 6-Year Follow-up Report from the Rhumadata® Clinical Database and Registry
Abstract Number: 429

Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment
Abstract Number: 430

Adoption of Treat to Target Management in the Context of Achievable Goals and Satisfaction in RA
Abstract Number: 431

Treatment Target in a Disease Activity Score Steered Treatment Protocol in Early Arthritis Patients: Low Disease Activity or Remission
Abstract Number: 432

Additional Intensive Treatment for Rheumatoid Arthritis Patients with Positive Power Doppler Signals Reduce the Radiological Joint Damage Even after Achieving Clinical Remission -SCRUM Study-
Abstract Number: 433

Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population
Abstract Number: 434

Duration of Remission By Currently Available Criteria Can Predict Physical Functioning, but Not Radiological Progression in Early Rheumatoid Arthritis Patients
Abstract Number: 435

Impact of Sarilumab on Fatigue, Pain, Morning Stiffness, Productivity, and Health Related Quality of Life (HRQoL) in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti-TNF-Î± Therapy: Results from a Phase 3 Study (RCT)
Abstract Number: 436

Ultrasonographic Disease Activity in Rheumatoid Arthritis Patients Who Are in Clinical Remission According to Different Remission Criteria: Should We Insist on Achieving Boolean Remission?
Abstract Number: 437

Is Mode of Action Important When Switching Biologic Monotherapy in Rheumatoid Arthritis? Drug Adherence Results from the Swedish Ssatg Registry
Abstract Number: 438

Comparison of the Stanford and Indian Health Assessment Questionnaires for Disability Outcomes in a Phase 3, Randomized, Double-Blind, Active Comparator Study of Infliximab and Biosimilar Infliximab BOW15 in Rheumatoid Arthritis
Abstract Number: 439

Progression of Radiographic Joint Destruction in Patients with Rheumatoid Arthritis Treated with a Biologic Agent in Combination with Methotrexate Versus a Biologic Alone: A Systematic Review and Meta-Analysis of Randomized Trials
Abstract Number: 440

Clinical Characteristics of Rheumatoid Arthritis Patients Achieving HAQ Remission with 6 Months of Biologic Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].